Trial Profile
Epirubicine plus Cyclophosphamid followed by Docetaxel +/- Sunitinib before surgery for the treatment of patients with HER2neu-negative operable breast cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2013
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms ABCSG34; GA6182EI
- 07 Jun 2011 New trial record